Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.

Guan J, Fransson S, Siaw JTT, Treis D, Van den Eynden J, Chand D, Umapathy G, Svenberg P, Ruuth K, Wessman S, Shamikh A, Jacobsson H, Gordon L, Stenman J, Larsson E, Svensson PJ, Hansson M, Martinsson T, Kogner P, Palmer RH, Hallberg B.

Cold Spring Harb Mol Case Stud. 2018 Jun 15. pii: mcs.a002550. doi: 10.1101/mcs.a002550. [Epub ahead of print]

2.

Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation.

Guan J, Yamazaki Y, Chand D, van Dijk JR, Ruuth K, Palmer RH, Hallberg B.

Cancers (Basel). 2017 Oct 30;9(11). pii: E149. doi: 10.3390/cancers9110149.

3.

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.

Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson SP, Johnson TW, Smeal T, Martinsson T, Chesler L, Palmer RH, Hallberg B.

Dis Model Mech. 2016 Sep 1;9(9):941-52. doi: 10.1242/dmm.024448. Epub 2016 Jul 7.

4.

YopN and TyeA Hydrophobic Contacts Required for Regulating Ysc-Yop Type III Secretion Activity by Yersinia pseudotuberculosis.

Amer AA, Gurung JM, Costa TR, Ruuth K, Zavialov AV, Forsberg Å, Francis MS.

Front Cell Infect Microbiol. 2016 Jun 21;6:66. doi: 10.3389/fcimb.2016.00066. eCollection 2016.

5.

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.

Umapathy G, El Wakil A, Witek B, Chesler L, Danielson L, Deng X, Gray NS, Johansson M, Kvarnbrink S, Ruuth K, Schönherr C, Palmer RH, Hallberg B.

Sci Signal. 2014 Oct 28;7(349):ra102. doi: 10.1126/scisignal.2005470.

PMID:
25351247
6.

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, Abrahamsson J, Palmer RH, Noguera R, Hallberg B, Kogner P, Martinsson T.

Genes Chromosomes Cancer. 2015 Feb;54(2):99-109. doi: 10.1002/gcc.22223. Epub 2014 Sep 23.

PMID:
25251827
7.

Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.

Sattu K, Hochgräfe F, Wu J, Umapathy G, Schönherr C, Ruuth K, Chand D, Witek B, Fuchs J, Li PK, Hugosson F, Daly RJ, Palmer RH, Hallberg B.

FEBS J. 2013 Nov;280(21):5269-82. doi: 10.1111/febs.12453. Epub 2013 Aug 22.

8.

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.

Chand D, Yamazaki Y, Ruuth K, Schönherr C, Martinsson T, Kogner P, Attiyeh EF, Maris J, Morozova O, Marra MA, Ohira M, Nakagawara A, Sandström PE, Palmer RH, Hallberg B.

Dis Model Mech. 2013 Mar;6(2):373-82. doi: 10.1242/dmm.010348. Epub 2012 Oct 25.

9.

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.

Schönherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, Djos A, Martinsson T, Christensen JG, Palmer RH, Hallberg B.

Oncogene. 2012 Dec 13;31(50):5193-200. doi: 10.1038/onc.2012.12. Epub 2012 Jan 30.

PMID:
22286764
10.

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

Schönherr C, Ruuth K, Yamazaki Y, Eriksson T, Christensen J, Palmer RH, Hallberg B.

Biochem J. 2011 Dec 15;440(3):405-13. doi: 10.1042/BJ20101796.

PMID:
21838707
11.

The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo.

Schönherr C, Ruuth K, Eriksson T, Yamazaki Y, Ottmann C, Combaret V, Vigny M, Kamaraj S, Palmer RH, Hallberg B.

Transl Oncol. 2011 Aug;4(4):258-65. Epub 2011 Aug 1.

12.

Inhibition of cellular FLICE-like inhibitory protein abolishes insensitivity to interferon-α and death receptor stimulation in resistant variants of the human U937 cell line.

Blomberg J, Höglund A, Eriksson D, Ruuth K, Jacobsson M, Lundgren E, Nilsson JA.

Apoptosis. 2011 Aug;16(8):783-94. doi: 10.1007/s10495-011-0606-0.

PMID:
21562857
13.

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.

Martinsson T, Eriksson T, Abrahamsson J, Caren H, Hansson M, Kogner P, Kamaraj S, Schönherr C, Weinmar J, Ruuth K, Palmer RH, Hallberg B.

Cancer Res. 2011 Jan 1;71(1):98-105. doi: 10.1158/0008-5472.CAN-10-2366. Epub 2010 Nov 8.

14.

Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis.

Sundström P, Nyström M, Ruuth K, Lundgren E.

J Neuroimmunol. 2009 Oct 30;215(1-2):102-7. doi: 10.1016/j.jneuroim.2009.08.004. Epub 2009 Sep 5.

PMID:
19733917
15.

Reduced FAS transcription in clones of U937 cells that have acquired resistance to Fas-induced apoptosis.

Blomberg J, Ruuth K, Jacobsson M, Höglund A, Nilsson JA, Lundgren E.

FEBS J. 2009 Jan;276(2):497-508. doi: 10.1111/j.1742-4658.2008.06790.x. Epub 2008 Dec 4.

16.

Intrathecal morphine as a treatment for refractory restless legs syndrome.

Lindvall P, Ruuth K, Jakobsson B, Nilsson S.

Neurosurgery. 2008 Dec;63(6):E1209; author reply E1209. doi: 10.1227/01.NEU.0000325674.02282.CC. No abstract available.

PMID:
19057291
17.

Acquired resistance to Fas/CD95 ligation in U937 cells is associated with multiple molecular mechanisms.

Blomberg J, Ruuth K, Santos D, Lundgren E.

Anticancer Res. 2008 Mar-Apr;28(2A):593-9.

18.

No support for a truncated interferon-alpha 17 allele as risk factor for MS.

Nyström M, Ruuth K, Lundgren E, Sundström P.

Eur J Neurol. 2007 Nov;14(11):1302-4.

PMID:
17956450
19.

[Intrathecal morphine infusion a possible treatment in restless legs].

Lindvall PK, Ruuth K, Jakobsson B, Nilsson SK.

Lakartidningen. 2007 Aug 8-21;104(32-33):2250-2. Swedish. No abstract available.

PMID:
17822205
20.

Differential resistance of melanoma cells to treatment with recombinant IFN-alpha2b and leukocyte IFN.

Ruuth K, Berglund A, Munoz V, Lundgren E.

Anticancer Res. 2007 Jul-Aug;27(4B):2109-14.

21.

Successful treatment of restless legs syndrome with an implanted pump for intrathecal drug delivery.

Jakobsson B, Ruuth K.

Acta Anaesthesiol Scand. 2002 Jan;46(1):114-7.

PMID:
11903084
22.

Interferon-alpha promotes survival of human primary B-lymphocytes via phosphatidylinositol 3-kinase.

Ruuth K, Carlsson L, Hallberg B, Lundgren E.

Biochem Biophys Res Commun. 2001 Jun 15;284(3):583-6.

PMID:
11396940
23.

Brief intervention for male heavy drinkers in routine general practice: a three-year randomized controlled study.

Aalto M, Seppä K, Mattila P, Mustonen H, Ruuth K, Hyvärinen H, Pulkkinen H, Alho H, Sillanaukee P.

Alcohol Alcohol. 2001 May-Jun;36(3):224-30.

PMID:
11373259
24.

Effect of suramin on human interferon alpha binding to cell receptors.

Kandefer-Szerszeń M, Ruuth K, Lundgren E.

Arch Immunol Ther Exp (Warsz). 1997;45(1):93-9.

PMID:
9090447
25.
26.

Characterization of monoclonal anti-DNA antibodies and visualization of binding to chromosomes and cell nuclei.

Malmqvist M, Carlsson J, Fredriksson BA, Johansson L, Matsson P, Nilsson B, Ruuth K.

J Immunol Methods. 1987 Oct 23;103(1):109-19.

PMID:
2443576

Supplemental Content

Support Center